According to a media release issued today by Progenics Pharmaceuticals, early clinical studies of two of their investigational products — the imaging agents [123I]-MIP-1072 and [123I]-MIP-1095 — suggest potential of these two agents in enhancement of imaging techniques to identify the exact location of cancer in bone, tissue, and the prostate itself. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: agent, imaging, MIP-1072, MIP-1095, MIP-1404 | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 